Skip to main content
Publications
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D , Bennett L , Proctor C, Gutierrez L , Andrews E, Johannes C . Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe . Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C , Odom D , Gutierrez L , Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union . Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043
Gallego R, Codony-Servat J, Garcia-Albeniz X , Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer . Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250